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ABSTRACT 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder affecting 
adrenal steroid synthesis. More than 95% of CAH cases are caused by reduced 21-
hydroxylase function leading to variable extent of cortisol and aldosterone deficiency in 
addition to androgen excess. The foundation of CAH treatment is the use of 
glucocorticoids. However, overtreatment leads to Cushing’s syndrome and 
undertreatment to hyperandrogenism and Addisonian crisis. 
The aims of this thesis has been to evaluate the impact of CAH and its treatment on 
some factors that could lead to a reduced quality of life and increased morbidity or 
mortality during adult life. 
In total 93 patients (32 males) with CAH and 93 (32 males) age- and sex-matched 
controls were studied. Subgroups of different ages (<30 years or older), phenotypes and 
the three most common genotype groups (null, I2 splice and I172N) were studied.  
Focus was on cardiovascular and metabolic risk, bone health in females and fertility in 
males.  
Cardiovascular and metabolic risk: Younger female and male patients and controls had 
similar waist/hip ratio, lean and fat mass and insulin values. Older females had higher 
waist/hip ratio, lean mass and insulin values than controls. Fat mass was similar to 
controls but higher than in younger patients. Lipid profiles were slightly more 
favourable in older patients than in controls. Gestational diabetes was more common in 
patients. Few older female patients had hypertension, cardiovascular disease or 
diabetes. Despite moderate glucocorticoid doses, most patients had suppressed 
androgens. Serum liver enzymes were elevated in patients compared to controls. In 
patients, liver enzymes were correlated with waist circumference and with total body 
and trunk fat. Liver enzymes were increased even in non-obese patients mainly 
attributed to the patients ≥30 years who also demonstrated elevated insulin levels and 
HOMA-indices. In older males, waist/hip ratio, fat mass, and gamma-glutamyl 
transpeptidase were higher and heart rate faster than in controls. Insulin levels were 
increased during oral glucose tolerance test in all and older patients. Homocysteine was 
lower in all and in younger male patients which may be cardioprotective. Adverse 
cardiovascular profiles were mainly found in the mild genotype I172N. This group had 
normal urinary epinephrine concentrations whereas the more severe genotypes null and 
I2 splice had low levels. Few old male patients had cardiovascular disease and no 
patient had diabetes.  
Bone health in females: Patients had lower bone mineral density (BMD) than controls 
at all measured sites. In patients ≥30 years old 73% were osteopenic or osteoporotic vs 
21% in controls. BMD was similar in the two classic forms and had no obvious 
relationship to genotypes. More fractures were reported in patients than controls. 
Fertility in males: Compared to national data the fertility was impaired in CAH males. 
The lifetime number of partners was smaller in all patients, in older patients and in the 
null group. Testicular tumours (TARTs) were found in 86% and 47% had pathological 
semen. Those with pathological semen had increased total and truncal fat mass, fat/lean 
mass ratio and heart rate. FSH was elevated and correlated negatively with sperm count 
and concentration.  
Conclusions: Adult CAH females and males have a number of issues due to the disease 
and to corticoid supplementation. However, the findings in this thesis are more positive 
than many of the previous reports on CAH. Many parameters studied in our CAH 
individuals <30 years were not different from age- and sex-matched controls. This is 
likely to reflect improvements in management. 
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1. INTRODUCTION AND BACKGROUND 
 
In 1865 the Neapolitan professor of anatomy Luigi De Crecchio described an 
astonishing case (De Crecchio 1865). He reported on the autopsy of a certain Joseph 
Marzo who had a 6 cm long penis with first grade hypospadias and no testes but with 
normal vagina, uterus, tubes, and ovaries. Moreover, the adrenal glands were clearly 
enlarged. Joseph had been considered a female at birth but had at 4 years of age been 
declared male. Prof De Crecchio conducted extensive interviews with people close to 
Joseph and all described him as a typical male socially and sexually. Joseph died in his 
40s after one of many episodes of vomiting and diarrhea. This is the first reported case 
of congenital adrenal hyperplasia (CAH) and the description is still relevant today. 
 
CAH is an autosomal recessive disorder affecting adrenal steroid synthesis. More than 
95% of CAH cases are caused by reduced 21-hydroxylase function leading to variable 
degree of cortisol and aldosterone deficiency together with adrenal androgen excess 
(Merke and Bornstein 2005). The impaired cortisol secretion causes ACTH levels to 
rise and stimulate adrenocortical hormone secretion, resulting in hyperplasia of the 
adrenal cortex, accumulation of the precursors immediately proximal to the 21-
hydroxylase enzyme in the pathway of cortisol and aldosterone synthesis, and the 
precursors are then directed into the androgen pathway (Fig. 1). Moreover, cortisol 
secretion from the adrenals is necessary for adrenomedullary organogenesis and 
epinephrine production which is therefore impaired in classic CAH (Merke and 
Bornstein 2005).  
 
1. 1 Clinical presentation of 21-hydroxylase deficiency 
Three distinct phenotypes are recognized in CAH due to 21-hydroxylase deficiency: 
salt-wasting (SW), simple virilizing (SV), and non-classic (NC) CAH. SW and SV are 
usually called classic CAH with newborn females demonstrating virilized external 
genitalia. This is in contrast to affected boys who have no overt signs of CAH except 
variable and subtle hyperpigmentation and penile enlargement. Males and females 
with SW phenotype have severe aldosterone deficiency resulting in salt loss which may 
be life-thretening in the neonatal period if not recognized and adequately treated.   
 
 2 
Fig 1. Synthesis of steroid hormones in the adrenal cortex. The pathways of cortisol, aldosterone, and 
androgen synthesis and the different enzymes involved are shown.  21-hydroxylase is the enzyme most 
frequently deficient in congenital adrenal hyperplasia and is highlighted together with steroids elevated in 
this condition. Genes coding for the various enzymes are shown within brackets. From Falhammar et al 
2010 Anthropometry in Congenital Adrenal Hyperplasia. In Handbook of Anthropometry: Physical 
Measures of Human Form in Health and Disease. Springer, USA. In Press.  
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Males with SV phenotype usually present with early virilization at age 2-4 years 
(Merke and Bornstein 2005), but cases with much later presentation, even during adult 
life, have been described.   
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The virilization of external genitalia in females demonstrates a wide range from very 
mild to severe with complete masculine appearance. In case of minimal clitoromegaly 
and fusion between the vagina and urthra near the perineum, surgery may be 
unnecessary. In the past the management of genital surgery has varied between clinics 
both with respect to extent of surgery and at what age it should be performed (6 months 
and 9 years) (Nordenskjöld et al 2008). It is nowadays recommended that the first 
surgery is done between 2 and 6 months and only in specialized centers to improve the 
surgical results and quality of life (Clayton et al 2002, Nordenskjöld et al 2008). If 
further surgery is needed it should, if possible, wait until the girl has reached 
adolescence and can make her own decision (Clayton et al 2002). 
Severe neonatal virilization in girls can lead to erroneous sex assignment (White and 
Speiser 2000). These females are more likely to be brought up as males in cultures 
that value boys more than girls and/or in developing countries where the diagnosis 
often is delayed (Abdullah et al 1991, Kademir and Yordam 1997). However, even in 
the developed world, the female internal genitalia may escape discovery until late in 
life (Ravichandran et al 1996). 
In NC CAH females, external genitalia are normal at birth, but signs and symptoms of 
androgen excess often develop in both males and females during the peripubertal 
period or in adulthood (New 2006). In NC females over 10 years of age the presenting 
symptoms reported were hirsutism (59%), oligomenorrhea (54%), acne (33%), 
infertility (13%), clitoromegaly (10%), alopecia (8%), primary amenorrhea (4%) and 
premature pubarche (4%) (Moran et al 2000). NC can also be found in the work-up of 
miscarriages, even late ones (Bidet et al 2010, Falhammar 2010).The symptoms and 
signs may be indistinguishable from those in the polycystic ovary syndrome (PCOS) 
(Falhammar et al 2008a), and exclusion of CAH is a prerequisite for the diagnosis of 
PCOS (Azziz et al 2009). Little has been published about males with NC CAH, and 
they are usually found during family screening (New 2006). Overrepresentation in 
males with severe acne may occur (Placzek et al 2005, Sharquie et al 2009). It has been 
claimed that all individuals diagnosed with NC based on genetic testing will develop 
signs of hyperandrogenism over time, including those who were initially 
asymptomatic (Levine et al 1980, New 2006). However, even in females symptoms 
and signs are sometimes very discrete and NC CAH may not be diagnosed until old age 
by coincidence (Falhammar and Thorén 2005).  
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1. 2 Neuropsychology  
Androgens have been proposed to exert an organizational effect on higher brain 
function during fetal development and an activating effect during puberty (Goy and 
McEwen 1980). In females with CAH, having elevated prenatal and early postnatal 
adrenal androgens, the organizational effects of androgens on the developing brain have 
been studied. Since the 1960s numerous studies have demonstrated the masculinized 
behavior in girls with CAH e.g. regarding childhood play behavior, aggressive 
behavior, and spatial perception (Ehrhardt et al 1968, Berenbaum and Resnick 1997, 
Nordenström et al 2002, Hines et al 2003). Moreover, increased frequency of left-
handiness in females with CAH has been proposed (Nass et al 1987), but has not been 
confirmed by others (Helleday et al 1994).  
Prenatal androgens are believed to have a dose-dependent rather than a threshold effect. 
We found convincingly in our cohort of adult CAH women a high frequency of gender-
atypical behavior regarding choise of occupations, spare time interests, and sports 
(Frisén et al 2009). The behavior was correlated with the severity of the CYP21A2 
mutations, and was most marked in genotypes with unmeasurable enzyme activity. 
Sexual orientation was also affected. Overall, bi- and homosexuality was present in 
19% of the patients, being 50% in the most severe genotype group and declining with 
milder mutations.  
 
1. 3 Neonatal screening 
Early recognition and treatment of CAH due to 21-hydroxylase deficiency can prevent 
serious morbidity and mortality. The disease is appropriate for neonatal screening due 
to its relative commonness and can quite easily be diagnosed by 17-
hydroxyprogesterone (17OHP) determination from a dried blood spot sample on filter 
paper. Currently, 49 states in the US and as a minimum 16 other countries have 
newborn screening for CAH, and 13 additional countries have pilot or local screening 
programs (White 2009). In Sweden newborn screening started in 1986 and clear 
benefits have been demonstrated as lowered age of definite diagnosis in boys from 21 
days to 9 days, no more death reported due to neonatal salt-wasting, and virtually 
eradication of salt-losing crisis. Roughly half of the diagnosed CAH babies did benefit 
from the screening and the cost was reasonable (USD 26 700 per case CAH found) 
(Thilén et al 1998). No screening program will however detect all NC 21-hydroxylase 
deficiencies without an unacceptably high number of false positive cases. Thus, NC 
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CAH is still usually diagnosed by clinical signs and symptoms in older children and 
adults. 
 
1. 4 Prevalence of 21-hydroxylase deficiency 
Data from 13 neonatal screening programs (USA, France, Italy, New Zealand, Japan, 
UK, Brazil, Switzerland, Sweden, Germany, Portugal, Canada, and Spain) with more 
than 6.5 million newborns included demonstrated that 21-hydroxylase deficiency is 
quite common with a frequency of the classic form of one in 15 000 livebirths (Merke 
and Bornstein 2005). In Sweden the frequency was higher with one in 9 800 affected 
(Thilén et al 1998). Thus, the carrier incidence is roughly one in 50 individuals. 
However, the incidence of classic 21-hydroxylase deficiency varies widely depending 
on ethnicity and geographical location being highest in two very isolated areas with 
relatively small populations: the Ypic Eskimos in Alaska (one in 282), and on the 
island of La Réunion in the Indian Ocean (one in 2 141), but even a big cosmopolitan 
city as Rome in Italy has a high frequency (one in 5 580 Caucasians) (Pang et al 1988). 
In contrast, classic 21-hydroxylase deficiency is rare in Afro-Americans (one in 42 
309) (Therrell et al 1998). 
NC CAH is much more prevalent than classic CAH. In New York City with a very 
heterogenous population one in 111 was affected. Divided into different ethnicities the 
prevalence of the disease was in: Ashkenazi Jews 3.7%, Hispanics 1.9%, former 
Yugoslavs 1.6%, Italians 0.3%, and the remaining Caucasian population 0.1% (Speiser 
et al 1985). The high prevalence in the Caucasian population makes NC CAH due to 
21-hydroxylase deficiency the most frequent autosomal recessive disorder in man (New 
2006). 
 
1. 5 Diagnosis 
The biochemical hallmark of 21-hydroxylase deficiency is the elevation of 17OHP, the 
main substrate for 21-hydroxylase (Fig.1). In neonates a concentration of 17OHP > 240 
nmol/L in a random blood sample is diagnostic of classic 21-hydroxylase deficiency 
(Merke and Bornstein 2005). The reference level is < 3 nmol/L at 3 days in a full-term 
infant. Premature, sick or stressed newborn babies have higher levels of 17OHP than 
healthy, term babies leading to many false-positive tests (White 2009). These newborns 
may need serial measurements of 17OHP to confirm or rule out classic CAH (Clayton 
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et al 2002). Typically, newborns with most severe genotypes have higher 17OHP 
concentrations than the other phenotypes (Nordenström et al 1999).  
When the diagnosis is suspected later in childhood and onwards most experts advocate 
an early morning 17OHP as screening. A value < 2.5 nmol/L in children and < 6.0 
nmol/L in adults will normally exclude CAH (Merke and Bornstein 2005). It has been 
estimated that 11% of NC CAH will be missed by this approach, at least in adults 
(Bachega et al 2000). Thus, if the clinical suspicion remains in spite of a normal basal 
17OHP, the gold standard for diagnosis is the ACTH-stimulation test (250 mg of 
cosyntropin iv), with measurement of 17OHP at 60 min. NC CAH has traditionally 
been diagnosed by basal 17OHP > 15 nmol/L and/or ACTH-stimulated 17OHP > 30 
nmol/L in males and in females during follicular phase (Bachega et al 2000). However, 
it was found in 58 patients with NC CAH that the ACTH-stimulated 17OHP levels 
ranged from 51 to 363 nmol/L (Bachega et al 2000). Consequently, it has been 
suggested to increase the ACTH stimulated cut-off value to > 45 nmol/L, and to allow 
testing at any time of the day and at any day during the menstrual cycle (Merke and 
Bornstein 2005). In patients with classic CAH, basal and ACTH-stimulated 17OHP 
will exceed 300 nmol/L.Twenty-four hour urinary pregnanetriol, the urinary metabolite 
of 17OHP, can be used to diagnose 21-hydroxylase deficiency (White and Speiser 
2000), but normal values can be found in NC CAH. Two other variants of CAH with a 
different clinical presentation, 3β-hydroxysteroid dehydrogenase type 2 deficiency in 
women and 11β-hydroxylase deficiency in both sexes have rarely been misdiagnosed 
as 21-hydroxylase deficiency but will be identified by the serum steroid pattern 
following ACTH stimulation and/or the urinary steroid profile (White and Speiser 
2000). The diagnosis is preferably confirmed by gene mutation analysis, which is 
particularly important in cases with symptoms and borderline elevation of 17OHP.  
 
1. 6 Molecular genetics of CYP21A2  
The structural gene encoding human 21-hydroxylase is a microsomal cytochrome 
P450 named CYP21A2 (CYP21, or CYP21B). CYP21A2 and the homologous inactive 
pseudogene, CYP21A1P (CYP21P, or CYP21A) are located in a complicated structure 
within the HLA major histocompatibility complex on chromosome 6p21.3 
approximately 30 kb apart (Fig. 2). The genes are close to and alternating with the 
genes encoding the fourth component of serum complement, namely factor C4B and 
C4A (Carrol et al 1985, White et al 1985). CYP21A2 and CYP21A1P each contain 10 
exons with 98% homology of nucleotide sequences in the exons and roughly 96% in 
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the introns (Higashi et al 1986, White et al 1986). In spite of their almost identical 
nucleotide sequences, only CYP21A2 is functional while CYP21A1P is a pseudogene 
with a number of harmful sequences. The similarities and proximity between the two 
genes predispose exchange of material. Approximately 95% of all mutations causing 
21-hydroxylase deficiency are deletions/large gene conversions of the entire CYP21A2 
and/or a few point mutations that have been transferred from the inactive CYP21A1P to 
the active CYP21A2 with the remaining 5% of the mutations occurring spontaneously 
without the involvement of the pseudogene (Wedell et al 1994, White and Speiser 
2000).  
 
Fig 2. The CYP21A2 gene encoding steroid 21-hydroxylase is located in the HLA class III region in the 
major histocompatibility (MHC) locus on the short arm of chromosome 6 (band 6p21.3) together with a 
highly homologous pseudogene, CYP21A1P. Both genes are arranged in tandem repeat with the C4A and 
C4B genes encoding the fourth component of complement. The C4/CYP21 unit is flanked by a telomeric 
RP gene and a centromeric TNX gene, forming what is referred to as RCCX modules (RP-C4-CYP21-
TNX). Most haplotypes have a bimodular form composed of two sets of four genes arranged in tandem. 
Illustration kindly supplied by Prof Anna Wedell. 
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The frequency and spectrum of the most common mutations are similar between 
populations, even though some minor differences may exist between different ethnic 
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populations. In a Swedish cohort CYP21A2 was entirely missing on 29.8% of the 
chromosomes, and the following point mutations were the most prevalent:  I2 splice 
(27.7%), I172N (20.8%), V281L (5.4%), and R357W (3.8%) (Wedell et al 1994). 
 
1. 7 Correlations between genotype and phenotype 
Unlike most genetic diseases, a good genotype-phenotype correlation has been found in 
21-hydroxylase deficiency (Wedell et al 1994, Jääskeläinen et al 1997), although some 
exceptions may occur. The advantage of performing mutation analysis is that the 
clinical presentation can be predicted and serious consequences prevented. Moreover, 
mutation analysis confirms the diagnosis.  
The milder mutation of the two affected alleles determines the phenotype. Although 
three different phenotypes exist, four distinct genotype groups can be identified with 
the mildest allele representing the group: null, I2 splice, I172N and NC genotype. Null 
refers to mutations completely abolishing enzyme activity and is associated with the 
SW phenotype. I2 splice retains a very low but measurable level of activity and is 
usually associated with SW but in a few cases SV. I172N is less severe and most often 
found in SV, but is rarely associated with SW. The final group includes mutations such 
as V281L and P30L with enzyme activities of between 30 and 50% and is associated 
with NC (Fig. 3) (Wedell et al 1994, White and Speiser 2000). 
 
1. 8 Uncommon variants  
As mentioned above, 21-hydroxylase deficiency constitutes about 95% of all CAH. 
Deficiencies of other adrenocortical enzymes shown in Fig. 1 can also be involved 
causing other phenotypes. All variants are, however, associated with cortisol 
insufficiency.  
The most common CAH variant after 21-hydroxylase deficiency has an incidence of 
about one in 100 000 in the general population (White and Speiser 2000). This variant, 
11β-hydroxylase deficiency, exhibits elevated levels of the steroid precursors 
deoxycorticosterone (DOC) and 11-deoxycortisol (Fig.1).  
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Fig. 3 The common, pseudogene-derived mutations in CYP21A2, their corresponding clinical disease 
presentations, and their residual activities assayed after expression of recombinant enzyme in vitro. 
Illustration kindly supplied by Prof Anna Wedell. 
P453S
V281LP30LI172NI2 splice
Deletion
Del 8 bp E3
Cluster E6
L307insT
Q318X
R356W
Null:
Mutation:
In vitro act: <1% 2-10% 30-50%
SWCAH severity: SV NC
 
DOC is a strong mineralocorticoid, and affected patients show decreased serum 
potassium and hypertension which is also found in 17α-hydroxylase deficiency due to 
accumulation of DOC and another mineralocorticoid precursor, corticosterone. These 
two precursors have a weak glucocorticoid activity preventing salt-losing crisis, being 
rare in both 11β-hydroxylase and 17α-hydroxylase deficiency. 
Genital ambiguity is not only a neonatal presentation of 46,XX individuals affected by 
21-hydroxylase deficiency or 11β-hydroxylase deficiency, but is also found in  46,XY 
individuals affected by 17α-hydroxylase deficiency. Two CAH variants can display 
genital ambiguity in both sexes, 3β-hydroxysteroid dehydrogenase type 2 deficiency 
and P450 oxidoreductase deficiency. The genes for these four CAH variants are well 
studied and mutation analyses are available (Krone and Arlt 2009).   
 
1.  9 Treatment 
The foundation of CAH treatment is the use of glucocorticoids that will substitute the 
cortisol insufficiency and decrease ACTH production and secretion leading to lower 
adrenal androgens. Glucocorticoids first became available in the beginning of the 
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1950s. No currently living SW CAH individuals were born before the introduction 
since they did not survive the neonatal period. The launch of glucocorticoids led to 
survival and control of symptoms. Later, fear of long-term side effects of 
supraphysiological glucocorticoid supplementation has emerged. Nowadays, the 
practice is to give the lowest possible dose that suppresses excessive adrenal androgen 
and steroid precursor secretion and replaces cortisol deficiency. This is almost an 
impossible task as glucocorticoid doses needed to normalize androgens are often 
supraphysiological and there is no consensus regarding which laboratory and clinical 
parameters should be used to monitor therapy in adults. 
Hydrocortisone (10–15 mg/m2/day divided in three doses) has been recommended as 
the glucocorticoid of choice during childhood as it is considered to affect growth less 
than other preparations (Clayton et al 2002). Cortisone acetate has to be converted to 
cortisol for biological activity and this conversion can be impaired due to low 11β-
hydroxysteroid dehydrogenase activity and is therefore a less favourable alternative 
(Nordenström et al 1999). Intermediary-acting glucocorticoids, such as prednisolone 
(5.0–7.5 mg per day divided in two doses) and long-acting glucocorticoids, such as 
dexamethasone (0.25–0.50 mg at bedtime or divided in two doses), may be an option at 
or near the completion of linear growth (Merke and Bornstein 2005). In adults the 
glucocorticoid of choice is often prednisolone (Ogilvie et al 2006, Nermoen et al 2010, 
Arlt et al 2010). In contrast to hydrocortisone, prednisolone and dexamethasone have 
minimal mineralocorticoid effect in the doses given.  
Mineralocorticoid replacement is achieved with fludrocortisone and is usually 
mandatory in SW, but is also recommended in SV as it allows management with lower 
doses of glucocorticoids (Clayton et al 2002, Merke and Bornstein 2005). All 
individuals with 21-hydroxylase deficiency have some degree of aldosterone 
insufficiency, even NC patients (Fiet et al 1989), and mineralocorticoids have 
sometimes been used in NC (Falhammar et al 2008a, Williams et al 2010, Arlt et al 
2010). The dose should be adjusted to maintain plasma renin in the range from mid-
normal to slightly elevated. A typical daily dose of fludrocortisone ranges from 0.1 mg 
to 0.2 mg with higher doses in infancy and lower in adulthood. Very low doses are 
often used in older adults (0.05-0.025 mg) due to risk of side-effects (hypertension and 
oedema). Of note is that the dose is independent of body size. Salt tablets are usually 
used in infancy in addition to fludrocortisone (White and Speiser 2000).  
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1. 10 Outcome 
Overall, data from children with CAH are quite abundant while data concerning adults 
are scanty. Most studies of adults with CAH have exclusively recruited patients up to 
30 years of age and the majority of studies in adults have no or only few males 
included. Thus, information on the situation for adults with 21-hydroxylase deficiency 
aged ≥ 30 years is limited and studies are needed. 
 
1. 10. 1 Metabolic and cardiovascular risk profiles 
The long-term use of slightly supraphysiological glucocorticoid doses is potentially 
harmful and may bring an increased risk of obesitas, type 2 diabetes, dyslipidemia, 
hypertension and cardiovascular morbidity and mortality to patients with CAH. 
Previous reports on cardiovascular and metabolic risk profiles in adults with CAH have 
been conflicting, few parameters have been studied and mainly young adults below the 
age of 30 years have been included. In spite of an equal prevalence in males and 
females, predominantly females have been studied (Speiser et al 1992, Paula et al 1994, 
Cameron et al 1995, Hagenfeldt et al 2000, Stikkelbroeck et al 2003, Bayraktar et al 
2004, Christiansen et al 2004, Saygili et al 2005, Hoepffner et al 2006, King et al 2006, 
Bachelot et al 2007, Sartorato et al 2007, Kroese et al 2009, Arlt et al 2010). These 
issues have recently been reviewed (Kim and Merke 2009, Mooij et al 2009).  
 
1. 10. 1. 1 Body composition 
BMI. Obesity is an important risk factor for type 2 diabetes and cardiovascular 
morbidity and mortality. Most studies have found increased BMI in adults and children 
with CAH (Helleday et al 1993, Cornean et al 1998, Hagenfeldt et al 2000, Paganini et 
al 2000, Stikkelbroeck et al 2003, King et al 2006, Völkl et al 2006a, Bachelot et al 
2007, Völkl et al 2009, Arlt et al 2010), but not all (Cameron et al 1995, Guissinye et al 
1997, Williams et al 2010). To avoid adult obesity, the management from infancy and 
onwards is extremely important. Over-treatment during infancy increased the risk of 
obesity in childhood despite adequate treatment for several years thereafter (Knorr et al 
1988). Prepubertal children were shown to have increased BMI also when growth was 
unaffected. Normally, BMI increases rapidly to a peak in infancy and then reverses 
before increasing again later in childhood. An early age for this rebound is considered a 
reliable indicator of future adult obesity. Children with CAH had an earlier adiposity 
rebound by three years compared with the normal population. BMI SDS was greater 
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than one in all but one patient (of 22) in spite of unchanged height SDS (Cornean et al 
1998). Parental obesity is another predisposing factor to childhood obesity. A 4.86 
increased relative risk of obesity, defined as BMI > 2 SDS, has been reported in CAH 
children and adolescents with obese parents (Völkl et al 2006a).  
 
Body circumferences. However, BMI is not an ideal estimate of body fat. For instance, 
body builders have elevated BMI but a very small proportion of body fat. Visceral 
obesity is an established risk factor for cardiovascular disease and type 2 diabetes. 
Waist circumference and the waist to hip ratio are established anthropometric 
measurements used for estimating visceral obesity and truncal fat. These measurements 
are better predictors of adverse outcomes than BMI (Ness-Abramof et al 2008). In spite 
of this, measurements of body circumferences have not been reported widely in CAH. 
In a small study of children affected with CAH aged 1.6 – 10.5 years, waist, hip, upper 
arm, and femur circumferences were increased compared to controls (Isguven et al 
2008). The waist to hip ratio was, however, increased in girls while it was decreased in 
boys. A recent larger study of adults with CAH found increased waist circumference in 
females but not in males compared to national data (Arlt et al 2010). 
 
DXA assessment of body composition. As mentioned above, BMI can be unreliable as 
an estimate of body fat in persons with CAH. Especially undiagnosed or poorly 
controlled females will have high androgen levels, leading to muscular hypertrophy 
(Fig. 4). High physical activity can also contribute (Frisén et al 2009). On the other 
hand, in physically very inactive patients or in those on severe overtreatment with 
glucocorticoids (exogenous Cushing´s syndrome), lean mass may be low and BMI may 
underestimate fat mass. Hence, a more reliable method of estimating body fat and lean 
mass is needed in addition to anthropometric measurements in individuals with CAH. 
Dual energy X-ray absorptiometry (DXA) provides a fairly accurate, reliable, and 
simple way of measuring total and regional fat and lean mass. Four studies in children 
and young adults with CAH each including 13-30 subjects (Cameron et al 1995, 
Hagenfeldt 2000, Stikkelbroeck et al 2003, Christiansen et al 2004) have all 
demonstrated increase in fat mass. Interestingly, two of the studies only found 
increased fat mass in male but not in female CAH patients (Cameron et al 1995, 
Christiansen et al 2004). 
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Fig. 4 Figure illustrating a short woman with classic CAH, poor compliance to glucocorticoid 
medication, and signs of muscular hypertrophy. Her serum testosterone was markedly elevated (16 
nmol/L; reference interval in adult females 0.3 - 3.0 nmol/L, in adult males 10 - 30 nmol/L). From 
Falhammar et al 2010 Anthropometry in Congenital Adrenal Hyperplasia. In Handbook of 
Anthropometry: Physical Measures of Human Form in Health and Disease. Springer, USA. In Press. 
  
 
1. 10. 1. 2 Liver enzymes 
Increased frequency of elevated aminotransferase activity and signs of nonalcoholic 
fatty liver disease (NAFLD) have been reported in PCOS (Schwimmer et al 2005, Setji 
et al 2006). NAFLD is associated with increased risk of overall death compared to the 
general population (standard mortality ratio 1.34), with diabetes and cirrhosis being risk 
factors for death. It has been shown that subjects with NAFLD and elevated liver 
enzymes are at increased risk of developing metabolic complications, being three times 
more likely to develop type 2 diabetes and 50 % more likely to develop the metabolic 
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syndrome compared with the general population (Adams et al 2009). Thus, NAFLD 
and elevated liver enzymes are markers for increased future metabolic risk and could 
further predict the metabolic risk of CAH individuals. The frequency of NAFLD and/or 
liver enzymes has not been reported in CAH. 
 
1. 10. 1. 3 Glucose, insulin, and lipids 
No study has demonstrated increased frequency of diabetes in CAH but all have shown 
increased insulin resistance (Paula et al 1994, Speiser et al 1992, Charmandari et al 
2002, Saygili et al 2005, Sartorato et al 2007, Völkl et al 2009, Williams et al 2010) 
except one (Bayraktar et al 2004). The latter study differed however, as only NC CAH 
patients  were  included, the diagnosis was not confirmed genetically and none of these 
patients was on glucocorticoid medication. Moreover, a recent study showed improved 
insulin sensitivity with pioglitazone treatment (Kroese et al 2009). Interestingly, in a 
recent study, only NC children and not classic CAH children were insulin resistant 
presumably due to adverse metabolic effects of prolonged postnatal androgen excess in 
NC (Williams et al 2010). Very few studies have included individuals over 30 years of 
age. Another way of predicting future type 2 diabetes is to study gestational diabetes. 
The frequency of this condition has not yet been reported in CAH. Studies of serum 
lipid profile in CAH have, in contrast to insulin resistance, shown normal values 
(Bayraktar et al 2004, Sartorato et al 2007, Bachelot et al 2007). 
 
1. 10. 1. 4 Blood pressure 
Studies evaluating blood pressure in patients with CAH have found divergent results 
(Sartorato et al 2007, Roch et al 2003, Völkl et al 2006b, Williams et al 2010, Arlt et al 
2010). Single measurements in 29 adults with a mean age of 28 were normal and there 
were no differences compared with controls (Sartorato et al 2007), while in a large 
cohort of 199 adult 21-hydroxylase deficient patients (median age 34 years) females 
with classic phenotype demonstrated increased diastolic pressure compared to national 
data (Arlt et al 2010). On the other hand in children and adolescents, a single 
measurement of blood pressure was similar to controls in classic CAH while increased 
in NC CAH compared to controls (Williams et al 2010), and 24h ambulatory blood 
pressure measurements were elevated in classic CAH (Roch et al 2003, Völkl 2006b).   
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1. 10. 1. 5 Intima-media thickness 
Intima-media thickness, a predictor of clinical arteriosclerosis and associated with 
cardiovascular risk, has been demonstrated to be elevated in adult individuals with 
CAH (Sartorato et al 2007). However, no individual had clinical cardiovascular disease, 
probably due to the small number (n = 19) and the fact that the subjects were too young 
to have manifest disease (mean age 28 ± 3.5 years). 
  
1. 10. 2 Bone health  
 
1.  10. 2. 1 Final height 
Both over- and undertreatment with glucocorticoids during childhood and adolescence 
can compromise height development. Several studies of both males and females with 
CAH have verified a decreased final height. A meta-analysis of 18 studies published 
between 1977 and 2001 found that height was -1.37 SD under population mean which 
is equivalent to -10 cm (Eugster et al 2001). Later studies have confirmed this 
(Balsamo et al 2003, Arlt et al 2010), but also shown the importance of 
mineralocorticoid supplementation to optimize final height (Balsamo et al 2003). Early 
diagnosis and treatment improved height development in many (Bergstrand 1966, 
Eugster et al 2001, Balsamo et al 2003), but not in all studies (Urban et al 1978, 
Kirkland et al 1978, DiMartino-Nardi et al 1986). Good compliance to treatment is also 
important for a favourable outcome (Eugster et al 2001). 
 
1. 10. 2. 2 BMD 
It is well established that endogenous Cushing´s syndrome and pharmacological 
glucocorticoid therapy can generate osteoporosis via multiple mechanisms resulting in 
increased bone resorption followed by suppression of bone formation. Decreased 
intestinal calcium absorption and increased renal calcium excretion may lead to 
secondary hyperparathyroidism. Insulin-like growth factors, their binding proteins and 
the secretion of gonadal steroids may also be affected (Shaker and Lukert 2005). Data 
are conflicting concerning the effect of long-term glucocorticoid replacement therapy 
on bone mass and bone metabolism in patients with CAH. In adults bone mineral 
density (BMD) has been reported to be normal (Guo et al 1996, Mora et al 1996, 
Stikkelbroeck et al 2003, Christiansen et al 2004), or decreased (Jääskeläinen and 
Voutilainen 1996, Hagenfeldt et al 2000, Sciannamblo et al 2006, King et al 2006, 
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Bachelot et al 2007, Arlt et al 2010). In children and young adults BMD was found to 
be increased (Arisaka et al 2001), normal (Girgis et al 1997, Fleischman et al 2007) or 
decreased (Zimmermann et al 2009). Moreover, some studies of children found 
decreased BMD in males (Cameron et al 1995), at puberty (Paganini et al 2000) or in 
long-term treated girls (de Almeida Freire et al 2003). The discrepancies may reflect 
differences in age of patients, type and severity of enzyme deficiencies and various 
therapeutic regimes. If there is an increased prevalence of fractures, the ultimate 
outcome of decreased BMD, has not been documented probably due to the small 
number of CAH individuals studied, their low mean age and that fractures not have 
been recorded. 
 
1. 10. 3 Fertility 
 
1. 10. 3. 1 Female fertility 
The frequency of pregnancies among women with CAH has constantly been reported 
as low compared with age-matched controls (Mulaikal et al 1987, Jääskeläinen et al 
2000a, Krone et al 2001, Lo and Grumbach 2001, Gastaud et al 2007). In our cohort of 
62 women with 21-hydroxylase deficiency only 16 had ever been pregnant compared to 
41 of 62 age-matched controls. Moreover, the number of children was 25 in the women 
with CAH compared to 54 in controls. The fertility rate was clearly related to the 
severity of the CYP21A2 mutation with no term pregnancy in the null group, 13% in 
the I2 splice group, 33% in the I172N group and 50% in the group of mutations 
consistent with NC CAH (Hagenfeldt et al 2008). The suggested reasons for low 
fertility in CAH women have been: delayed psychosexual development, low sexual 
activity, adrenal overproduction of androgens and steroid precursors, PCO, neuro-
endocrine factors, and genital surgery (Jääskeläinen et al 2000a, Otten et al 2005). 
However, in our patients presented in details above, the main reason for lower fertility 
was that few lived in heterosexual relationships and few had ever tried to become 
pregnant. All CAH women who tried to become pregnant had succeeded, sometimes 
after some medical help, except for a few of the older patients (Hagenfeldt et al 2008). 
 
1. 10. 3. 2 Male fertility 
Increased adrenal androgens due to undertreatment with glucocorticoids leading to 
gonadotropin suppression can impair male CAH fertility (Claahsen-van der Grinten et 
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al 2009) and similar signs and symptoms may also be found in overtreatment (Reisch et 
al 2009). However, testicular adrenal rest tumours (TARTs) are considered the most 
important reason for reduced fertility.  
Aberrant adrenal cells descend in the embryological period together with the testes in 
the majority of males. It is believed that these cells disappear if not stimulated. If 
adrenal cells are present and stimulated TARTs may arise. TARTs have receptors for 
both ACTH and angiotensin II, and high levels due to undertreatment with 
corticosteroids in CAH can enhance their growth (Claahsen-van der Griten 2007b). 
They are typically located in the rete testis and are associated with risk of obstruction of 
the seminal ducts, with subsequent permanent testicular damage. Few TARTs can be 
found by clinical examination as normally only TARTs > 2cm are detectable by 
palpation due to their location, buried within the testis (Claahsen-van der Grinten et al 
2009). TARTs have been found in CAH children with a frequency of about 20% and 
down to 6 years of age (Claahsen-van der Griten et al 2007a, Martinez-Aguayo et al 
2007). However, an old autopsy study found TARTs in 3 of 7 CAH boys less than 8 
weeks (Shanklin et al 1963). TARTs have been diagnosed by palpation, ultrasound or 
MRI. The highest frequency of TARTs reported has been 94% (Stikkelbroeck et al 
2001), while others report a prevalence of 0 - 69%, which probably reflects differences 
in mode of detection and age of patients (Urban 1978 et al, Avila et al 1996, 
Jääskeläinen et al 2000b, Cabrera et al 2001, Reisch et al 2009, Mouritsen et al 2010, 
Arlt et al 2010). TARTs are considered the most common reason for male CAH fertility 
problems which has been reported to be anything from normal (Urban et al 1978) to 
severely impaired (Jääskeläinen et al 2000b). The divergent results may be due to 
different modes of evaluation.   
To suppress ACTH secretion by intensifying corticosteroid treatment is not always 
successful in reducing the TART size. Even in well-controlled CAH males with normal 
or suppressed plasma ACTH levels, TARTs have been found (Walker et al 1997, 
Stikkelbroeck et al 2004). In fact, parameters of hormonal control were positively 
correlated with adrenal volume but not TART volume (Reisch et al 2010). Thus, other 
unknown factors must also contribute to tumour growth.  
When no decrease of the TARTs can be achieved with increased doses of corticoids, or 
if there is persistent azoospermia despite tumour reduction, testis-sparing surgery could 
be considered. Two small case series on steroid unresponsive TARTs have reported 
good results (Walker et al 1997, Tiryaki et al 2005). However, in a study of eight 
infertile males with 21-hydroxylase deficiency and TARTs, gonadal dysfunction and 
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oligo-azoospermia did not improve by surgery suggesting permanent damage of the 
surrounding testicular tissue (Claahsen-van der Grinten et al 2007c). The authors’ 
conclusion was that surgery is only indicated for relief of pain and discomfort caused 
by TART. If surgery was still considered for longstanding TARTs, it should only be 
performed when testicular biopsies have demonstrated viable testicular tissue 
preoperatively. 
However, TARTs may be present in CAH males who have children and a better 
indicator of fertility is semen analysis. Semen quality has recently been reported to be 
very poor in CAH males with all samples being pathologcal (Reisch et al 2009). But 
only one viable sperm is necessary to father a child and 22% had fathered children. In a 
Finnish study the child rate in CAH males was evaluated and compared with that of the 
whole Finnish male population with equal age distribution (Jääskeläinen et al 2000b). 
The CAH males had a child rate of 0.07 compared to 0.34 in the population. However, 
gonadotropin and inhibin B levels were similar to age-matched controls suggesting 
normal fertility. Thus, sexual and psychosocial factors may, like in CAH women 
discussed earlier, be a factor of importance for impaired fertility in CAH males. This 
has not been studied previously.  
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2. AIMS OF THE STUDY 
 
The overall goal of this thesis has been to evaluate the impact of CAH and its treatment 
on some factors that could lead to reduced quality of life and increased morbidity or 
mortality during adult life.  
 
The specific aims were to study in adult patients with CAH: 
 
 Body composition in females and males (Paper I and III) 
 Cardiovascular and metabolic risk factors in males and females (Paper I, II 
and III) 
 Bone health in CAH including final height in males and females (Paper I and 
III) and bone mineral density and fracture prevalence in females (Paper IV) 
 Fertility and fecundity in CAH males (Paper V)  
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3.  MATERIALS AND METHODS 
 
3. 1  Subjects  
In total 93 patients with CAH and 93 age- and sex-matched controls were studied. The 
females were recruited by an appeal to all Swedish Departments of Gynaecology, 
Endocrinology, and Internal Medicine; advertisement in the Journal of the Swedish 
Medical Association; and information to the national CAH patient organization, 
whereas the male patients were recruited mainly from the two participating centers. 
 In all patients, diagnoses were verified by review of original pediatric and adult records 
including genital examinations, laboratory reports of adrenal steroids, and mutation 
analyses. All patients had 21-hydroxylase deficiency apart from one male who had 3-
beta-HSD deficiency. Seventy-two (22 males) of the patients were recruited and 
examined at the Karolinska University Hospital and 21 (10 males) at the Sahlgrenska 
University Hospital.  
Characteristics of the recruited females and males with CAH are given in Table 1. Two 
patients in Paper V deserve a more detailed presentation. In a 61-year-old patient with 
male phenotype (SV, genotype group I2 splice), a female karotype was diagnosed at 
age 7, the internal genitalia were extirpated, and glucocorticoid and testosterone 
treatments were initiated. He was working full-time in an academic profession, was 
happily married and had two adopted children. He had always had a male gender 
identity and had no objection what so ever to having been raised as a man. One 21-
year-old male had been diagnosed with 3-beta-HSD deficiency (SW, genotype: C75R) 
as newborn, had ambiguous external genitalia at birth and surgery for hypospadias at 6 
month of age; at inclusion he presented male external genitalia with micropenis. He 
was working full-time in a low qualified work, lived alone and had no children.  
To find suitable controls to all recruited females and males, the National Population 
Registry was used. An invitation letter was sent to the person with the same sex in the 
National Population Registry following each patient. If these persons declined 
participation or did not answer despite reminding letters, the next person was invited 
and so on. Infants delivered at the same maternity ward at the same date were usually 
next to each other in the National Population Registry and were, or at least had been, 
living in the same area. The only exclusion criterion was severe mental or psychiatric 
disturbance with inability to consent to the study.  
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Table 1. Characteristics of the recruited adult females and males with CAH. 
   Number, n (%) Age, yrs  
Median (range) 
Both sexes  All 93 (100) 32 (18-67) 
  All 61 (100) 30 (18-63) 
  < 30 years 27 (44.3) 24 (18-29) 
  ≥ 30 years 34 (55.7) 35 (30-63) 
Females  SW 27 (44.3) 30 (18-47) 
 Phenotypes SV 28 (45.9) 32.5 (18-63) 
  NC 6 (9.8) 29.5 (23-63) 
  Null 13 (21.3) 30 (18-34) 
 Genotype  I2 splice 15 (24.6) 30 (20-47) 
 groups I172N 25 (41.0) 33 (18-63) 
  NC 6 (9.8) 29.5 (23-63) 
  All 32 (100) 34.5 (19-67) 
  < 30 years 10 (31.3) 22.8 (19-29) 
  ≥ 30 years 22 (68.7) 38.6 (30-67) 
Males  SW 18 (56.2) 32.6 (19-52) 
 Phenotypes SV 12 (37.5) 38.1 (21-67) 
  NC 2 (6.3) 38.5 (31-45) 
  Null 7 (21.9) 34.6 (21-52) 
 Genotype I2 splice 12 (37.5) 33 (19-61) 
 groups I172N 9 (28.1) 34.4 (21-67) 
  NC 3 (9.4) 36.6 (31-45) 
 
3. 2  Study protocol 
 
3. 2. 1 Female patients and controls (Paper I, II and IV) 
A medical history was obtained from all female patients and controls. In addition, all 
participants answered questionnaires on social situation and previous and present 
health. Previous fractures were asked for. A general physical examination was 
performed including anthropometry (height, weight, waist and hip circumference). 
Blood pressure, supine and standing, was registered and signs of hypo/hypercortisolism 
and hyperandrogenism were recorded.  
Blood samples were collected in the morning after an overnight fast for measurements 
of serum lipids [total cholesterol, triglycerides, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cholesterol], liver enzymes [serum alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
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and gamma-glutamyl transpeptidase (GGT)], electrolytes, plasma glucose, hormones 
[insulin, IGF-I, IGF-binding protein (IGFBP)-1, testosterone, DHEAS, androstenedione 
in all subjects and 17OHP, plasma ACTH, renin, PTH in patients], and β-C telopeptide 
of type I collagen (CTX). Twenty-four hour urinary pregnanetriol was measured only 
in the patients and samples were collected just prior to or after the examination. Total 
and regional fat and lean mass, and whole body, lumbar spine and femoral neck BMD 
were measured with DXA. 
Results concerning anthropometry, metabolic and cardiovascular risk markers and body 
composition are presented in Paper I, liver function tests and their association to body 
composition and other parameters in Paper II, and fracture prevalence, bone mineral 
density and markers for bone metabolism in Paper IV.  
 
3. 2.  2 Male patients and controls (Paper III and V) 
The investigation of the male patients and controls was carried out in the same 
manner as in the females but some additional items were included. The questionnaires 
contained in addition to health and social factors items related to sexuality, fertility, 
and fecundity. Fecundity problems were defined as trying to father > 1 year. 
Estimations of testicular volume using orchidometer as well as assessment of 
testicular consistency and tumours were included in the physical examination. In 
addition, testicular ultrasound and analysis of a semen sample were included in the 
protocol. A 24h ambulatory blood pressure and heart rate monitoring started at the 
end of the main examination day. After collection of fasting blood samples an oral 
glucose (75 g) tolerance test (OGTT) followed. A morning urinary spot sample was 
collected for albumin determination. Catecholamines were analyzed in 24h urine 
samples. In patients, 24h urinary pregnanetriol and a diurnal 17OHP curve using 
dried blood spots were analyzed. Results associated with cardiovascular and 
metabolic risk factors are presented in Paper III and results concerning sexual 
function, fertility, fecundity, testicular function and imaging in Paper V. 
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3.  3 Methods  
 
3. 3. 1 Body composition and BMD 
Total and regional body fat, and lean mass, whole body, lumbar spine (L2–L4), and  
femoral neck BMD, were estimated by DXA in 57 CAH women and 60 control 
subjects using a Lunar Model DPX-L or Prodigy equipment (Lunar Radiation, 
Madison, WI) using a standard procedure as previously described (Mazess et al 1990). 
The two instruments were calibrated to each other. The body composition parameters 
lean mass and fat mass were divided by height
2
 (kilograms per square meter) when 
analyzed to adjust for the difference in height between patients and controls. BMD 
values expressed as g/cm
2
 were compared in patients and controls. BMD was also 
expressed as SD scores (SDS) from the mean of an age and sex-matched reference 
group (Z-score) provided by the manufacturers and SDS from the mean of young adults 
(T-score). In three CAH women, BMD was assessed by Hologic QDR 4500 (Hologic 
Inc., Waltham, MA) instead, and only T- and Z-scores were used. The World Health 
Organization (WHO) definitions of osteopenia and osteoporosis were applied (i.e. T-
score between -1 and  -2.5 SD at any measured site was defined as osteopenia, and 
values below -2.5 SD were defined as osteoporosis) (WHO 1994). However, the WHO 
criteria were set up to be applied to postmenopausal women, and not to premenopausal 
women with presumably low peak bone mass. Despite this, these criteria were 
preferred to identify different degrees of low bone mass.  
The volume adjusted bone mineral apparent density (BMAD g/cm
3
) was calculated of 
the vertebrae and femoral neck in order to explore the impact on the results of the 
differences in skeletal dimensions between the women, who were on average 6.8 cm 
shorter, and the age-matched controls, using the formulas previously proposed (Carter 
et al 1992): BMAD = bone mineral content (BMC)/bone area
1.5
 for lumbar spine, and 
BMC/bone area
2
 for femoral neck. To whole body measurements another formula was 
used: BMAD = BMC/ (bone area
2
/ height) (Katzman et al 1991). Comparisons of Z-
scores between patients and controls in the height range of 160 – 169 cm were applied 
as another method of controlling the influence of the height difference.  
In males 32 CAH individuals and 31 controls were evaluated by the same principles as 
above all by Lunar Model Prodigy equipment but mainly body composition is 
presented in the thesis. 
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3. 3. 2 Glucocorticoid supplementation 
The doses of glucocorticoids were converted to hydrocortisone equivalents using: 
antiinflammatory equivalents (30 mg hydrocortisone = 37.5 mg cortisone acetate = 7.5 
mg prednisolone = 0.75 mg dexamethasone) (Liddle 1961); and growth-retarding 
equivalents (30 mg hydrocortisone = 37.5 mg cortisone acetate = 6 mg prednisolone = 
0.375 mg dexamethasone) (Miller 1991). Thereafter, body surface area (BSA) was 
calculated as the square root of (height [cm] x weight [kg])/3600 (m
2
) and was used to 
specify hydrocortisone equivalents in mg/m
2 
(Mosteller 1987). 
 
3. 3. 3 Blood pressure and heart rate 
 In males ambulatory 24h blood pressure and heart rate were determined with Meditech 
ABPM-05 (Meditech Ltd, Budapest, Hungary). An active (06:00 – 23:00) and a passive 
(23:00 – 06:00) part of the day were analyzed separately. 
 
3. 3. 4 Testicular examination  
The testicular ultrasounds were completed by one physician using a Voluson Expert 
730 machine equipped with a 12 – 16 MHz real-time four-dimensional linear 
transducer (GE Healthcare, Kretz, Austria). Total testicular, TART and functional 
(total testicular-TART) volumes were estimated using the formula for a prolate 
ellipsoid (length x width x height x 0.523) (Fleischen et al 1990). The total number of 
TARTs in both testicles was summarized and noted.  
 
3. 3. 5 Semen analysis  
Seminal fluid was collected by the CAH males after 1 - 4 days of ejaculatory 
abstinence. The analysis included estimation of semen volume, sperm concentration, 
total sperm count, motile and immotile spermatozoa and morphology. Semen was 
evaluated according to the WHO standard (WHO 1999). The samples were divided 
into two groups: normal or pathological. A doubling of the WHO cut-off for normal 
sperm concentration to > 40 million/mL has been proposed and was also used as a 
stricter criterion for normality (Bonde et al 1998).  
 
3. 3. 6 Hormones in serum and plasma 
Serum DHEAS, serum PTH and plasma ACTH were measured on an Advantage 
automatic immune analyzer and plasma renin by immunoradiometric assay (both 
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from Nichols Institute Diagnostics, San Clemente, CA). The reference limits of PTH 
were 12 – 55 ng/L, ACTH 2.0 – 10 pmol/L and renin in standing position 4 – 46 
ng/L. Serum insulin and testosterone were measured by fluoroimmunoassay 
(AutoDelfia; Wallac Inc, Turku, Finland). The reference value for fasting insulin was 
< 20 mU/L. To calculate the insulin resistance with a single fasting glucose and 
insulin value the HOMA-index [insulin/(22.5e-In glu)] was used (Matthew et al 
1985). A HOMA-index ≥ 2.77 has been suggested to indicate insulin resistance 
(Bonora et al 1998). Bioactive testosterone was calculated with consideration of total 
testosterone, SHBG and albumin (Vermeulen et al 1999). To analyze serum IGF-I 
(Bang et al 1991), IGFBP-1 (Povoa et al 1982), 17OHP (CIS BioInternational, Gif-
sur-Yvette, France), and androstenedione (DiaSorin S.p.A., Saluggia, Italy) RIA 
methods were used. A calculation of the regression line of the IGF-I concentrations in 
448 healthy subjects, aged 20 – 96 years, was used to express IGF-I as SDS (Hilding 
et al 1999). The reference limits for serum 17OHP were 0.6 – 2.5 nmol/L (follicular 
phase), 2.2 – 6.5 nmol/L (midcycle phase), 2.5 – 10 nmol/L (luteal phase), and 0.5 –
2.0 nmol/L (menopause). Sexual hormone binding globulin (SHBG), dried blood spot 
17OHP [measured at 08:00 (reference < 6 nmol/L), 14:00, 19:00, 01:00, and 06:00], 
FSH, LH, estradiol, total and free PSA were measured by fluoroimmunoassay 
(AutoDelfia, PerkinElmer, Waltham, MA). FSH and LH values between 1.0 - 10 U/L 
were considered normal. Prolactin was measured by immunoassay (Beckman Coulter 
Inc, Fullerton, CA); values between 3-13 μg/L were considered normal. 
 
3. 3. 7 Hormones in urine 
Urinary pregnanetriol was determined by gas chromatography and gas 
chromatography-mass spectrometry (Axelsson et al 1981). The reference limits were 
< 6 μmol/24 h (follicular phase and in males) and < 8 μmol/24 h (luteal phase). High 
performance liquid chromatography was used for determination of 24h urinary 
epinephrine and norepinephrine (reference limits < 80 and < 400 nmol/24h, 
respectively). 
 
3. 3. 8 Routine clinical chemistry and bone markers 
 Serum cholesterol, triglycerides, HDL, ALP, ALT, AST, GGT, Lipoprotein-(a) 
[Lp(a)], and plasma homocysteine and glucose were measured on SYNCHRON LX 
Systems (Beckman Coulter Inc., Fullerton, CA). LDL concentration was calculated 
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(Friedewald et al 1972). The reference limits for females given by the manufacturer 
were for ALP: < 3.8 μkat/L; ALT and AST: < 0.60 μkat/L (the proposed definition of  
ALT > 0.317 μkat/L [19 U/L] as pathological in women was also applied [Prati et al 
2002]); and GGT: < 0.80 μkat/L; and males ALP: < 1.9 μkat/L; ALT: < 1.20 μkat/L 
and GGT < 2.0 μkat/L. Serum CTX was measured on a Roche Elecsys 1010/2010 
immunoassay analyzer (Roche Diagnostics Ltd., Basel, Switzerland) with the 
reference limits of < 550 ng/L in premenopausal women and of < 1000 ng/L in 
postmenopausal women. Sodium, potassium, creatinine and urinary albumin were 
measured using routine assays. High performance liquid chromatography was used to 
measure hemoglobin A1c (HbA1c) by the MonoS method (reference limits 3.6 – 
5.3%). 
 
3. 3. 9 Statistics 
Data were analyzed using SigmaStat for Windows (Jandel Scientific, Erkarath, 
Germany). Results are presented as the mean ± SEM (Paper I, II and IV) or ± SD 
(Paper III and V) if not otherwise stated. Comparisons between two groups were 
made using the unpaired t test when values were normally distributed. Otherwise, the 
Mann-Whitney rank-sum test was used and, in these cases, the median and range are 
reported. When continuous variables were compared in three groups (Paper III and 
V), one-way ANOVA was used for normal distributions, otherwise the Kruskal-
Wallis test was performed, both followed by post hoc Bonferroni t or Mann-Whitney 
rank-sum test with Dunn’s method. Chi-square was used in frequency table 
calculations or, when the expected frequency was small (< 5), Fisher’s exact test. All 
proportions were calculated discounting missing values. In Paper I, III and IV 
correlations between continuous variables were assessed using linear and multiple 
regression analysis. In these cases, IGFBP-1, insulin, ACTH, testosterone (not in 
males), androstenedione, DHEAS, 17OHP, and pregnanetriol concentrations were log 
transformed before analysis to obtain a more closely approximated Gaussian 
distribution. Spearman’s correlation coefficient was used for correlation analyses in 
the remaining papers. Statistical significance was set at P < 0.05 and tendency at 
0.05–0.10.  
 
   27 
4. RESULTS AND DISCUSSION 
 
4. 1 Age at diagnosis and glucocorticoid therapy 
All included patients were born before the introduction of neonatal 17OHP screening. 
Thus, they were diagnosed on clinical suspicion. All individuals with the SW 
phenotype were diagnosed during the first weeks of life with salt-losing crisis (females 
and males) and the girls also presented ambiguous external genitalia. The females with 
the SV phenotype were diagnosed at 0 – 15 years of age with virilized external 
genitalia while the males were diagnosed at 3 – 28 years of age, both groups with mild 
or absent salt loss. NC females were diagnosed between 6 and 32 years of age and the 
males at 11 and 30 years of age both with nonambiguous external genitalia and no 
history of salt wasting (Paper I - V). The most commonly used glucocorticoid was 
prednisolone followed by hydrocortisone in both females and males. The 
glucocorticoid doses were similar in younger and older CAH females when comparing 
hydrocortisone equivalents (antiinflammatory equivalents: 18.1 ± 1.1 vs. 15.9 ± 0.9 
mg/m
2
; P = NS), and when comparing patients in the null, I2 splice, and I172N groups 
(17.8 ± 1.5 vs. 18.0 ± 1.2 vs. 15.9 ± 1.0 mg/m
2
; P = NS) (Paper I). In males, 
hydrocortisone equivalents were similar in younger and older CAH males (16.3 ± 3.6 
vs. 17.7 ± 5.6 mg/m
2
) or between the genotype groups null, I2 splice and I172N (19.3 ± 
3.5 vs. 16.2 ± 4.2 vs. 16.7 ± 7.2 mg/m
2
) (partly presented in Paper III). When 
comparing CAH females with males the differences in hydrocortisone equivalents were 
non-significant. 
 
4. 2 Cardiovascular morbidity  
As expected, no cardiovascular morbidity was found in females and males with CAH 
below 30 years of age but a few older individuals were affected (Paper I and III). In 
females the diagnoses were: myocardial infarction (n = 1), angina pectoris (n = 1), 
hypertension (n = 3), and hyperlipidemia (n = 2). There was no history of 
cardiovascular disease, use of statins or antihypertensives in the female controls. In 
males, cardiovascular disease was revealed in two patients and two controls. Genotype 
and phenotype of the 7 individuals with cardiovascular morbidity were five with I172N 
and all SV, one with V281L and NC, and one I2 splice with SW. Thus, the incidence of 
manifest cardiovascular disease, including treated hypertension and dyslipidemia, was 
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low (CAH adults: 7.7% vs controls: 2.1%), as expected, since only 7% of the females 
(Paper II) and 13% of males  (Paper III) were > 50 years old and the frequency of 
cardiovascular disease in female and males < 50 years old is very low (Booth et al 
2006). Consequently, larger studies with more individuals > 50 years are needed to 
clarify if CAH females and males have increased cardiovascular morbidity and 
mortality. In the meantime risk factor analysis is the only option available.  
 
4. 3 Body composition 
 
4. 3. 1 BMI and body circumferences 
 In younger females and males BMI, waist circumference, waist to hip ratio, body fat, 
and lean body mass were similar to age-matched controls (Paper I and III). In 
contrast, CAH women and men older than 30 years had higher BMI and waist to hip 
ratios than both age-matched controls and younger CAH women.  
 
4. 3. 2 Body composition studied by DXA 
 DXA measurements verified that total and regional fat and muscle mass were similar 
to controls in the younger CAH patients, whereas in the older group only males had 
increased total and truncal fat mass (Paper I and III). As previously mentioned, 
increased fat mass has been reported in young adults. Even increased fat mass only in 
male and not in female CAH patients has been observed (Cameron et al 1995, 
Christiansen et al 2004). The finding of elevated BMI but normal fat mass in older 
CAH females can be explained by a higher lean body mass than both controls and 
younger CAH females, while lean mass in older CAH males was similar to controls 
and to their younger counterparts. Interestingly, in contrast, lean mass was significantly 
higher in older than in younger control males. A strong correlation was found between 
lean mass and fat mass in females with CAH (Fig. 5) (Paper I). This was not found in 
males (CAH males: r = 0.311, P = 0.083; male controls: r = 0.178, P = 0.346). The 
reasons for the difference in body composition we found between older females and 
males with CAH are unclear and remain speculative. Overexposure to androgens in the 
CAH females in the past may have had a stimulatory effect on muscle mass but at the 
time of the present study, most females had suppressed androgens (Fig. 6).  
Older CAH males had lower testosterone compared to male controls in spite of similar 
muscle mass. Another reason for the increased lean mass in CAH females could be 
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their gender-atypical behavior, with physically demanding professions and spare time 
interests (Frisén et al 2009). However, if there were differences in the amount of 
physical activity between younger and older CAH women or between male and female 
patients has not been studied in detail. 
 
Fig. 5 Correlation between total lean mass/height
2
 and total fat mass/height
2
 in adult women with CAH.  
Filled triangles CAH women ≥ 30 years old or; unfilled triangles, CAH women < 30 years; filled circles, 
controls ≥ 30 years old; and unfilled circles, controls < 30 years. From Falhammar et al 2007 Metabolic 
profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency.  J Clin Endocrinol Metab 92:110-116. Copyright 2007, The Endocrine Society. 
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Fig 6. Serum androgens in adult women with CAH and controls. Filled circles, CAH women, those on 
antiandrogen excluded; filled triangles, CAH women on antiandrogen; and clear circles, controls. P < 
0.001 between CAH women and controls in all comparisons. Reference limits for the different androgens 
and different age intervals are indicated with dotted lines. From Falhammar et al 2007 Metabolic profile 
and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency.  J Clin Endocrinol Metab 92:110-116. Copyright 2007, The Endocrine Society. 
 
Younger CAH individuals and age- and sex-matched controls had similar body 
composition and this may reflect an improvement of therapy over time. Encouragement 
of physical activities, healthy food, and more optimal glucocorticoid therapy, as part of 
today’s management of CAH patients, may be the explanation of lower fat mass and 
BMI in our younger patients.  
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4. 4 Liver enzymes 
Elevation of liver enzymes can be a sign of NAFLD, which is associated with an 
increased risk of death (Adams et al 2007). Moreover, GGT has been demonstrated to 
be independently associated with cardiovascular mortality in a dose-response 
relationship even within the reference range (Ruttmann et al 2005). Women with CAH 
were found to have higher liver function tests (ALT, AST, GGT, ALP) than age- and 
sex-matched controls (Paper II). Compared with controls, patients with SW 
demonstrated elevation of all four liver enzymes, women with SV had only increased 
GGT and no differences were found in the six NC patients. In males we found elevated 
GGT in all males which was attributed to increase in older males and in the I172N 
genotype (Paper III). The increases were modest both in females and males, but 54% 
of women with CAH compared to 33% of controls displayed higher ALT using the 
lower cut off limit for women suggested (Prati et al 2002) (Paper II). We found 
positive correlations between liver enzymes and waist circumference (Paper II), and 
with trunk and total body fat measured by DXA (Paper II and III).  
One probable reason for higher liver enzymes in our patients compared to controls is 
increased liver fat storage supported by the positive associations to estimates of truncal 
fat. Positive correlations with BMI, waist to hip ratio and hepatic steatosis have been 
demonstrated previously (Lonardo and Trande 2000). Interestingly, when comparing 
non-obese CAH women and controls (i.e. BMI < 30 kg/m
2
 and waist circumference  
≤ 88 cm) patients still had elevated liver enzymes. The finding of higher liver function 
tests in non-obese CAH women than in non-obese controls suggests that not only 
central obesity but also glucocorticoids per se influence liver enzymes in women with 
CAH. Hepatic steatosis has been demonstrated both in endogenous Cushing’s 
syndrome (Rockall et al 2003) and in long-term pharmacological glucocorticoid 
therapy (Itoh et al 1977). In CAH the glucocorticoid doses needed to suppress elevated 
androgens are often slightly supraphysiological. Our female cohort had both markedly 
suppressed adrenal androgens (Fig. 6) and low bone mineral density, suggesting past 
and present overtreatment (Paper I and IV). We propose that the life-long 
glucocorticoid treatment is the most probable reason for higher liver enzymes in 
patients compared with controls. The cumulative life-time doses, not calculated in the 
present studies, have most likely been higher in older patients.   
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4. 3 Glucose, insulin, and lipids 
No increase of diabetes could be demonstrated. Only one CAH female ≥ 30 years old 
had elevated fasting plasma glucose and another had diet-controlled diabetes mellitus. 
The male cohort underwent a glucose tolerance test which was normal in all (Paper I 
and III).  
Compared to controls, women with CAH had lower fasting glucose levels in particular 
the younger patients. Insulin levels were similar to controls in younger patients and 
somewhat elevated in the older ones (Paper I). HOMA–index above the suggested 
level of insulin resistance (≥ 2.77) was found in 21% in the whole cohort of female 
patients and in 6% of controls (P = NS) with a trend to higher HOMA-indices in older 
patients (Paper II). In males glucose metabolism was similar in younger patients and 
controls, but older patients tended to have higher HbA1c compared to younger ones 
(Paper III). During OGTT, the area under the curve (AUC) for S-insulin was increased 
in all patients compared to controls. The 2h insulin level was higher in older patients 
than in their controls.  
S-IGFBP-1 was similar in all female groups (Paper I). As insulin is considered the 
principal regulator of hepatic production of IGFBP-1, hyperinsulinemia will lead to 
decreased levels of IGFBP-1 (Söderberg et al 2001). Hence, the expected negative 
relationship between IGFBP-1 and insulin was found both in patients and controls. 
Normal IGFBP-1 concentrations indicate that there was no major aberration in insulin 
sensitivity at the group level. 
Most reports to date have demonstrated increased insulin resistance in CAH (Paula et 
al 1994, Speiser et al 1992, Charmandari et al 2002, Saygili et al 2005, Sartorato et al 
2007, Völkl et al 2009, Williams et al 2010). Our findings are contradictory 
concerning our younger patients, where we were unable to demonstrate increased 
insulin resistance. The included CAH individuals in previous studies have been of a 
similar age or younger. The only study reporting normal insulin sensitivity is carried 
out in untreated NC CAH women (Bayraktar et al 2004). However, our older CAH 
patients did show indices of increased insulin resistance so the frequency of diabetes 
may be increased when this population gets older. The very modest increase in insulin 
concentrations despite higher BMI in the older female patients might be explained by 
a larger lean body mass. Some of the previous reports in children with classic CAH 
and adult women with NC CAH have shown higher insulin levels as well as higher 
testosterone concentrations than controls (Charmandari et al 2002, Saygili et al 2005). 
Elevated androgens in women may lead to insulin resistance (Livingstone and 
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Collison 2002). If the suppressed androgens in our women with CAH may have 
modified insulin sensitivity remains tentative.  
The HOMA-index has been the most frequently used method for evaluating insulin 
resistance in CAH. The test is based on fasting glucose and insulin. The low fasting 
glucose found in our patients (Paper I, II and III), which was probably due to 
cortisol insufficiency before the morning glucocorticoid medication may lead to 
underestimation of insulin resistance.   
Gestational diabetes is a strong predictor for future type 2 diabetes (Cheung and 
Helmink 2006) and the frequency was increased in CAH women (Paper I). Three of 
14 patients (21%), all in the older group, compared with none of 31 controls who had 
accomplished a full-term pregnancy, had a history of gestational diabetes. If this 
preliminary observation is verified in larger studies, the frequency is even higher than 
in the Australian Indigenous populations which have been considered to have one of 
the highest risks of diabetes in pregnancy (Davis et al 2009, Falhammar et al 2010). 
The doses of prednisolone (5 – 7.5 mg daily) during pregnancy in the CAH women 
when becoming diabetic did not differ from the other CAH females.  
We found, similar to previous studies (Bayraktar et al 2004, Bachelot et al 2007, 
Sartorato et al 2007), normal lipid values in younger CAH patients. Our older females  
had even more favorable lipid values than both younger CAH females and controls 
(Paper I), while older males had more unfavorable lipid values compared to younger 
ones (Paper III), possibly reflecting differences in lifestyle between older females and 
males with CAH. 
 
4. 4 Other cardiovascular risk markers  
Lp(a) has in many studies been associated with coronary heart disease and stroke 
(Emerging Risk Factors Collaboration 2009) and has not previously been measured in 
CAH. Lp(a) was found to be similar in male CAH patients and controls (Paper III). 
Several clinical and epidemiologic studies have recognized elevated blood 
homocysteine as a strong independent risk factor for cardiovascular disease in the 
general population (McCully 2007). Homocysteine has previously been analyzed in 
one study of NC CAH and found to be similar to that in controls (Bayraktar et al 2004). 
In contrast, homocysteine was decreased in younger male patients compared to controls 
and to older male patients which may give cardiovascular protection.  
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Albuminuria has been shown to be a marker of vacular dysfunctionan and even 
increasing urinary albumin in the reference range has been associated with increasing 
cardiovascular disease (Danziger 2008). Urinary albumin in CAH individuals has not 
been reported previously and tended to be increased in our cohort of older CAH males 
compared to controls.  
 
4. 5 Adrenomedullary function, blood pressure, and heart rate 
 
4. 5. 1 Adrenomedullary function 
 Adrenomedullary function was studied for the first time in a mature CAH cohort 
(Paper III). In our male patients, significantly reduced urinary epinephrine was 
convincingly demonstrated in the two more severe genotype groups (null and I2 splice), 
but not in the milder I172N group (Fig. 7). There was no difference between older and 
younger patients.  
Plasma epinephrine has been shown to be impaired in children, adolescents and young 
adults with classic CAH (Merke and Bornstein 2005, Weise et al 2004, Riepe et al 
2006, Green-Golan et al 2007). Adequate cortisol secretion from the adrenal cortex is 
necessary for normal adrenomedullary organogenesis and epinephrine production 
(Merke and Bornstein 2005). These adrenomedullary defects are certainly a result of 
insufficient prenatal cortisol production and were not ameliorated by postnatal 
glucocorticoid supplementation. Epinephrine insufficiency can aggravate Addisonian 
crisis in individuals with CAH and lead to hypoglycemia (Merke and Bornstein 2005). 
This, together with more severe mineralocorticoid deficiency, is probably the reason for 
more severe Addisonian crisis in SW, especially in the null genotype.  
 
4. 5. 2 Blood pressure 
We found no difference in supine blood pressure in adult females with CAH compared 
to controls (Paper I), which agrees with one of the two other reports on blood pressure 
in adult CAH (Sartorato et al 2007). There was a small, but significant, elevation of 
upright diastolic blood pressure in older CAH females not seen in younger CAH 
females (Paper I). If this has any clinical significance is uncertain. The other study 
with blood pressure reported in adult CAH patients reported also increased diastolic 
blood pressure, however, only sitting diastolic blood pressure in classic CAH females 
and not in NC females or classic CAH males (Arlt et al 2010). In males 24h ambulatory 
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blood pressure measurement was performed and no significant difference was seen 
between patients and control, irrespective of age group (Paper III). 
 
Fig. 7 Urinary catecholamines in adult males with congenital adrenal hyperplasia and in the three most 
common CYP21A2 (Null, I2 splice, and I172N) and age- and sex-matched controls. Box plot 
demonstrates the 10th, 25th, 50th, 75th and 90th percentiles. All P-values compared to controls if not 
indicated otherwise. P-value: *<0.05, **<0.01, ***<0.001, †= 0.057.  
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The two other reports on 24h ambulatory blood pressure measurements, both in 
children and adolescents, included almost exclusively SW individuals with only a small 
proportion of SV patients. They demonstrated, in contrast to our patients, elevated day 
and night time systolic pressures in CAH individuals (Roch et al 2003, Völkl et al 
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2006b). The median BMI in both reports was significantly elevated and the elevated 
systolic levels correlated with the degree of overweight and obesity explaining the 
difference to our leaner patients. 
 
4. 5. 3 Heart rate 
 An unexpected finding when analyzing the 24h ambulatory monitoring in CAH males 
and controls was increased heart rate in the CAH cohort as well as in the I2 splice and 
I172N groups compared to controls (Fig. 8) (Paper III). This increase was attributed to 
a higher frequency in the older patients. Our younger patients had normal heart rates in 
accord with previous studies of young patients (Weise et al 2004, Riepe et al 2006, 
Green-Golan et al 2007). In the older groups, the mean difference between patients and 
controls during night hours was 27 beats/min while it was lower during day time, 13 
beats/min. Increased heart rate is a known risk factor for cardiovascular and 
noncardiovascular death, especially in men, with some studies finding heart rate to be 
independent of other cardiovascular risk factors (Kannel et al 1987, Shaper et al 1993, 
Mensink and Hoffmeister 1997). Even a small increment in heart rate in the normal 
range can increase the cardiovascular risk. The heart rate in our CAH males was 
correlated with other cardiovascular risk factors. Decreased testosterone levels and the 
extent of glycemic control explained around 50% of the elevated heart rate. The 
adrenomedullary hypofunction in severe CAH is not likely to be involved as this would 
lead to a decreased heart rate. Cardiovascular effects of catecholamines are dependent 
on cortisol concentrations. This is probably not important because the mean 
glucocorticoid dose was similar in all groups.  
 
4. 6 Cardiovascular risk and age 
As presented above most metabolic and cardiovascular risk factors were elevated in 
older CAH individuals, especially in males, while they were normal in younger. Why 
the risk appears to be increased compared to age-matched controls is speculative but a 
higher lifetime exposure to exogenous glucocorticoids may be one explanation. 
Moreover, the majority of the older patients were treated in general pediatric care 
during childhood, but the younger ones have been treated within or with back-up from 
pediatric endocrinology units, most likely with a more optimal corticosteroid therapy 
and access to life-style interventions. 
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4. 7 Cardiovascular risk and genotype  
For the first time, the three most common CYP21A2 genotype groups and their 
association to cardiovascular and metabolic risk profiles were explored.  
In males, heart rate was elevated in the I172N and I2 splice groups (Fig. 8).  
 
Fig. 8 Heart rate measured with 24h ambulatory monitor in adult males with congenital adrenal 
hyperplasia, divided into younger than 30 years or older (upper panel), and into the three most common 
CYP21A2 genotype groups, (Null, I2 splice, and I172N) (lower panel) and age- and sex-matched 
controls. Box plot demonstrates the 10th, 25th, 50th, 75th and 90th percentiles. All P values compared to 
controls if not indicated otherwise. 
 
Moreover, there was an increased waist to hip ratio but also increased lean mass 
together with tendencies of increased BMI and fat mass in the I172N group, not seen in 
the null or I2 splice group. GGT was elevated in the I172N group, but not in the null or 
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I2 splice groups. The I172N genotype group had higher truncal fat mass than the other 
genotypes probably explaining their higher GGT (Paper III).  
The null genotype group had lower fasting insulin values than controls which tended to 
be lower than in the other groups. The I172N group had higher insulin AUC than 
controls and the other genotypes. Lp(a) was more unfavorable in the null group 
compared to the other genotypes. In the I172N group there was a tendency to a 
decreased homocysteine compared to controls. Urinary albumin tended to be increased 
in the I2 splice group compared to controls. A higher average 24h systolic and night 
diastolic blood pressure was found in the I172N group while the null and I2 splice 
groups had similar blood pressure as controls (Paper III).  
Thus, in males, as seen in table 2, a statistically significant increase in 5/10 risk 
parameters was found in the genotype group I172N, vs 1/10 and 0/10 in the I2 splice 
and null individuals. If this is attributed to a high dose of glucocorticoids and 
mineralocorticoids in I172N males (the doses were similar to those in null and I2 
splice) in relation to the milder CYP21A2 mutation or to a higher fat mass or if it is 
genotype specific is presently unclear. Moreover, none of the I172N males had been 
screened with 17OHP at birth and it can be speculated if a late diagnosis with 
prolonged postnatal androgen excess could lead to adverse metabolic effects. Some 
support of this can be found in a recent study where NC CAH boys and girls had more 
parameters of insulin resistance and higher systolic blood pressure compared to 
controls, which were not seen in classic CAH boys and girls (Williams et al 2010). 
These NC children were diagnosed on average more than 5 years later than the classic 
CAH children. One could also hypothesize that the demonstrated adrenomedullary 
hypofunction in our null and I2 splice groups could be a protective factor.  
Preliminary results in the female CAH cohort indicate a different pattern where all 
genotype groups have similar fat mass as controls and a higher lean mass in the null 
and NC group. In females liver enzymes were increased in all the three most common 
genotype groups compared to controls (Paper II). The differences between sexes may 
be attributed to earlier diagnosis in females and that they are more affected by adrenal 
androgens neuropsychologically and physically. Certainly there is a need for long-term 
follow-up and further studies of insulin sensitivity, cardiovascular and metabolic risk in 
adult CAH. 
   39 
Table 2. Genotype and cardiovascular risk factors in males with CAH 
 Null I2 splice I172N 
Waist/hip ratio ↔ ↔ ↑ 
Fat mass ↔ ↔ (↑) 
Blood pressure ↔ ↔ ↑ 
Heart rate ↔ ↑ ↑ 
Insulin ↔ ↔ ↑ 
Lipids ↔ ↔ ↔ 
GGT ↔ ↔ ↑ 
Lp(a) (↑) ↔ ↔ 
Homocysteine ↔ ↔ (↓) 
U-albumin ↔ (↑) ↔ 
Cardiovascular risk compared to controls: ↔ similar; ↑ increased; ↓ decreased. ( ) tendency. 
 
4. 8 Bone  health 
 
4. 8. 1 Final height 
In accordance with previous reports (Eugster et al 2001, Arlt et al 2010), we 
demonstrated that individuals with CAH were significantly shorter than controls (Fig. 
9) (Paper I and III). Males were more affected than females. Mean height SDS was    
-1.85 ± 1.3 in males and -1.3 ± 1.1 in females (P = 0.035) when compared to a Swedish 
reference population (Wikland et al 2002). As expected, patients with classic CAH who 
were diagnosed within the first year of life were significantly taller (P < 0.001) than 
those who were diagnosed later (Fig. 10). The mean difference in the females was 1.1 
SD (P < 0.001) but in the males only 0.4 SD (NS) in spite of the fact that diagnosis 
after the first year was present in 40 % of males vs 28 % of women and mean 
glucocorticoid doses were similar. This suggests that other circumstances affecting 
height development may differ between males and females, for instance compliance to 
medication. In classic CAH we also found a trend to a better height achievement in 
younger than in older patients, mean SDS being -1.2 ± 1.1 vs -1.7 ± 1.2 (P = 0.075), 
whereas there was no difference in the control group. This might reflect earlier 
diagnosis and improved management. 
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Fig. 9 A, Body height (centimeters) in 61 adult women with CAH and age-matched controls. B, Body 
height divided into SW, SV, and NC in patients. From Falhammar et al 2007 Metabolic profile and body 
composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  J 
Clin Endocrinol Metab 92:110-116. Copyright 2007, The Endocrine Society. 
 
 
4. 8. 2 BMD and fractures in females 
 
Both younger and older women with CAH exhibited lower BMD at all measured sites 
compared with controls (Fig. 11) (Paper IV). These differences were also found in 
subgroup analysis of patients with the three common classic genotypes (Fig.12) or with 
the SW and SV phenotypes. In the milder NC form, BMD did not differ between 
patients and controls. 
A total of 40 patients (62%) fulfilled the WHO criteria for osteopenia/osteoporosis 
compared with 10 controls (16%). The frequency of osteoporosis/osteopenia was also 
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significantly higher compared with controls in SW and SV patients and in the null and 
I172N genotype groups.  
 
Fig. 10 Mean final height SDS in relation to Swedish reference data in patients with classic CAH 
diagnosed before and after one year of age. The entire cohort (n = 86), females (n = 56), and males (n = 
30) are shown. ***P < 0.001, ns = not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMD differences between patients and controls were not attributed to the patients’ 
shorter height. When calculating volume-adjusted BMAD or comparing patients and 
controls within the same height range 160 – 169 cm differences persisted. 
Our finding of low BMD in females with CAH is in accordance with the majority of 
studies in adults (Jääskeläinen and Voutilainen 1996, Hagenfeldt et al 2000, 
Sciannamblo et al 2006, King et al 2006, Bachelot et al 2007, Arlt et al 2010), but not 
all (Guo et al 1996, Mora et al 1996, Stikkelbroeck et al 2003, Christiansen et al 2004). 
However, the latter four studies only included between 6 and 19 women each with 21-
hydroxylase deficiency and very few patients were above 30 years of age, probably 
explaining the difference. 
The ultimate outcome of decreased BMD, fractures, has not previously been reported. 
We found significantly more fractures in patients than in controls (31 fractures in 18 
CAH women vs. two fractures in two controls). 
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Fig. 11 BMD in 61 adult females with CAH due to 21-hydroxylase deficiency, and age- and sex-matched 
controls expressed as g/cm
2
 (A) and as T-score (SD) (B). Box plot demonstrates the 10th, 25th, 50th, 
75th, and 90th percentiles. From Falhammar H et al 2007 Fractures and bone mineral density in adult 
women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 92:4643-4649. Copyright 2007, The 
Endocrine Society. 
 
 
The difference between patients and controls in osteoporotic fractures (i.e. vertebrae, 
wrist, and hip) almost reached significance. Subgroups with significant differences in 
fracture prevalence compared with controls were: older women, the SW and SV groups 
and the genotypes null and Il72N. However, the trauma that led to fractures was not 
ascertained, thus we cannot entirely exclude that the differences in lifestyle between 
women with CAH and controls partly influenced the results.  
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Fig. 12 BMD in adult females with CAH due to 21-hydroxylase deficiency divided into three genotypes, 
with the mildest of the two mutations as representative of the genotype (Null/Null, n = 13; I2 splice, n = 
15; and I172N, n = 25), and age- and sex-matched controls expressed as g/cm
2
 (A) and as T score (SD) 
(B). Box plot demonstrates the 10th, 25th, 50th, 75th, and 90th percentiles. From Falhammar H et al 2007 
Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol 
Metab 92:4643-4649. Copyright 2007, The Endocrine Society. 
 
 
 
The bone resorption marker CTX was significantly lower in the older patients than in 
controls. This was unexpected, as it was previously observed both elevated CTX and 
bone-specific ALP concentrations when investigating young CAH individuals, some 
still growing (Sciannamblo et al 2006). The effect of elevated glucocorticoid doses on 
the skeleton comprises however an initial period of bone resorption when  bone density 
decreases rapidly followed by a slower progressive phase when bone mineral declines 
because of impaired bone formation (Canalis et al 2004). Possibly our female patients 
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treated for many years had predominantly low bone formation. Because we only 
measured total ALP, we cannot decide whether the slight increase in older CAH 
women was attributed to bone or liver-derived ALP.  
Preliminary, in CAH males we have found similar results of decreased BMD and 
increased frequency of osteoporosis/osteopenia. When comparing the CAH males and   
women, preliminary data show no difference in T- and Z-score in lumbar spine or 
femoral neck. Hence, in the management of CAH it is important to monitor BMD and 
optimize the glucocorticoid doses. Other measures are calcium and vitamin D 
supplementation, life-style intervention and when needed conventional 
pharmacotherapy to prevent future osteoporosis related fractures. 
 
4. 9 Fecundity, fertility, and sexuality in males 
Compared to controls, more fecundity problems were found in CAH males (Paper 
V). Ten percent (3/31) had tried to father but never succeeded compared to 3% 
among controls (1/32). One of these patients had, however, a child a year after being 
included in the study. The I172N genotype group reported more fecundity problems 
compared to controls and no fecundity problems were reported in the null group.  
Fertility was decreased when compared to national Swedish data (mean 0.9 children 
per CAH male vs 1.8 in national data [SCB 2005]) and was found in all three classic 
genotypes. Our results fall within the wide range of previous studies reporting from 
normal (Urban et al 1978) to severely impaired fertility (Jääskeläinen et al 2000b). In 
the latter study however, when examining a subset of the males their inhibin B values 
were normal indicating normal fertility. Thus, the low fertility may partly be due to 
psychosexual factors. 
In our CAH females, one reason for a low fertility rate was increased non-
heterosexuality being 50% in the null genotype (Frisén et al 2009). In contrast, no 
homo- or bisexuality was found in our male patients (Paper V). This is in agreement 
with the only other report on sexual orientation that included 9 CAH males (Hines et 
al 2004). Erroneous information from the medical profession may to some extent 
have influenced fertility. The CAH males aged > 50 years reported that they had been 
informed in their youth that all CAH patients were infertile. Some of them were now 
fathers but one man with a normal semen sample had never tried to have children due 
to this information! Our patients also had less sexual experience with different 
partners, especially those older than 30 years and the null genotype.The increased 
frequency of marriage with age seen in controls was not seen in patients. Most likely 
   45 
however, the main reason for decreased fecundity and fertility was the high frequency 
of TARTs being found in 86% of examined patients (74% were bilateral) which is 
similar to the high frequency reported by Stikkelbroeck et al (2001). The varying 
frequency in previous reports may partly be explained by differences in ages of 
included patients and the mode of detection, with our patients being the older and our 
ultrasound equipment the most advanced. A typical image demonstrating a TART 
from one of the patients is shown in Fig. 13. 
A recent study has reported higher frequency of TARTs in the null compared to I2 
splice genotype group, and no case of TART was found in the I172N group or in the 
NC patients (Mouritsen et al 2010). In contrast, we found TARTs in high frequency 
in all genotype groups including I172N. The higher mean age in our I172N patients 
(41 vs 24 years) probably explains the difference. We even found small TARTs in 
two of three NC genotype patients with normal ACTH, previously only reported with 
clearly elevated ACTH or AII (Claahsen-van der Griten et al 2009). 
Consistent with previous reports, only 10% of our TARTs were detected by manual 
palpation (Claahsen-van der Grinten et al 2009). Due to their location within the testis 
usually TARTs < 2 cm will escape detection. The three patients with palpable TARTs 
were all poorly controlled. In the whole patient cohort, no correlation between 
TARTs and ACTH or renin was found, but those with very poor control had smaller 
functional testicular volumes and a tendency to larger TARTs compared to rest of the 
CAH males.  
TART volume correlated positively with LH and negatively with sperm motility (just 
above the level of significance, P = 0.058) probably reflecting Leydig cell 
destruction. Total functional testicular volume, on the other hand was positively 
correlated with sperm concentration, sperm count and volume (tendencies), and 
testosterone/estradiol ratio. These associations are in favour of a negative impact by 
TARTs on testicular function described below. 
If the WHO criterion (WHO 1999) for sperm concentration was used, 7% (1/15) of 
samples were pathological. With the stricter criteria for normality 33% were 
abnormal (5/15) and applying all WHO criteria 47% (7/15) were pathological. A 
selection bias may however have influenced our results. Although not statistically 
significant, those who produced a sample reported more fecundity problems and had 
fewer biological children than those who refrained from semen analyses (Paper V). 
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Fig. 13 Steps in the 3D inversion rendering process of right testicle of a 30-year-old male with 
congenital adrenal hyperplasia (genotype null/null) with two children. Acquisition in the three 
orthogonal planes and the rendered volume in the bottom right box.  By eliminating the surrounding 
nonpertinent structures with the electronic scalpel the structures of interest were left as the final 
inverted and rendered volume. In this case it could be seen that the tumor was calcified and had a 
cystic structure (right bottom corner the tumor marked with an arrow). In the left upper box the tumor 
is marked with arrows (the size of the tumor was measured to be: 2.6 x 1.1 x 0.9 cm corresponding to a 
volume of 1.4 cm
3
). 
 
 
Producing a semen sample may be uncomfortable and a high motivation is needed for 
participation. Still, our results are  more favourable than those in a  recent report were 
semen quality was found  to be very poor in CAH males with 58% being pathological 
if the stricter criteria of sperm concentration were used or 100% if all WHO criteria 
were considered (Reisch et al 2009).  
All the poorly controlled patients with an ultrasound or a semen sample analysed 
were pathological (6/6 and 1/1 respectively). Only one of the poorly controlled had 
   47 
reported fecundity problems and 63% (5/8) had biological children. None of the NC 
patients had a semen sample analysed, however, one had fathered three children. 
FSH levels were significantly increased compared to controls in the entire CAH 
group and in subgroups and was negatively correlated with total sperm count and 
sperm concentration (Fig. 11).   
 
Fig. 11 Correlation between FSH and total sperm count (left panel, Spearman’s correlation = -0.620, P 
= 0.012) or sperm concentration (right panel, Spearman’s correlation = -0.756, P < 0.001) in CAH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
These findings strongly indicate Sertoli cell dysfunction in CAH males. On the other 
hand, LH was no different from controls. None showed suppression of gonadotropin 
levels below the normal range. Decreased values of testosterone/estradiol ratio were 
found in patients due to decreased concentrations in older patients and could possibly 
affect fecundity and fertility. However, the lower ratio in patients with pathological 
semen was not significantly different compared to patients with normal semen. 
The CAH males with abnormal semen demonstrated higher truncal and total fat mass, 
total fat/lean mass ratio, and heart rate, thus showing increased metabolic and 
cardiovascular risk, in addition to fecundity issues. These signs are compatible with 
overtreatment with glucocorticoids, even though all groups had similar 17OHP levels 
and corticosteroid doses at the time of the study. Moreover, the I172N genotype 
group had a tendency to poorer sperm parameters compared to the I2 splice patients, 
possibly reflecting their negative cardio-metabolic profile (Paper IV), since increased 
metabolic risk has been associated with decreased fertility and impaired sperm quality 
(Kasturi et al 2008). One of the I172N males had for example severe teratozoospermi 
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with impaired motility and had previously been subjected to intracytoplasmic sperm 
injection (ICSI) resulting in one child. 
The patient with 3-beta-HSD deficiency had hardly any normal testicular tissue left as 
both testes were full of TARTs. His semen sample contained no sperms but a biopsy 
was able to retrieve approximately 100 severely abnormal sperm which were saved 
for future ICSI. Thus he was infertile. Fertility in 3-beta-HSD deficiency has not 
previously been studied (Pang 2001). 
Some of our patients with TARTs had experienced increased doses of 
glucocorticoids, surgery, biopsy and ICSI which may be one of the explanations why 
most of our males with CAH due to 21-hydroxylase deficiency who wished to father 
children appeared to be able to eventually. 
 
4. 10 Limitations 
The major limitations of the present study are, despite being larger and including older 
CAH individuals than most others, its size and involvement of few individuals >50 
years old. Negative findings must be interpreted with caution as the studies have 
limited power and the mean age of women was only 30 and of men only 35 years. 
Larger studies including more individuals above 50 years of age are needed to finally 
determine the long-term consequences of CAH, and to evaluate if the genotype 
influences the outcome.  
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5. CONCLUSIONS 
 
The present thesis aimed to evaluate some long-term consequences of CAH and its 
treatment. Little has previously been reported, especially concerning individuals with 
CAH above the age of 30 years. Our main focus was on cardiovascular and metabolic 
risk profiles in females and males, bone health in females, and sexuality and fertility in 
males. 
There was no clear evidence of unfavorable cardiovascular risk factors. Few patients 
had hypertension, manifest cardiovascular disease, or diabetes. Older patients, 
however, had higher BMI and waist to hip ratio than controls. Older women with 
CAH also had higher lean mass than controls. Adults with CAH had raised liver 
enzymes compared to controls. Only the group ≥ 30 years of age in both females and 
males, the null, I2 splice and I172N genotypes in women and the I172N group in 
males, demonstrated elevation of liver enzymes compared to controls. Women and 
men with CAH may have increased frequency of NAFLD. The occurrence of 
gestational diabetes was significantly elevated, indicating an increased risk for type 2 
diabetes in the future.  
We demonstrated that epinephrine concentrations were very low in the null and I2 
splice groups while in the slightly less severe genotype, I172N, the concentrations 
were normal. Increased heart rate was found in older CAH males, the I2 splice and 
the I172N group. Moreover, the I172N group also demonstrated increased blood 
pressure together with indices of increased body fat and insulin levels indicating a 
higher cardiovascular risk not seen in the males with the null genotype.  
Both women and men with CAH were shorter than age- and sex-matched controls. The 
frequency of fractures was significantly elevated in women with CAH 30 years or 
older. Moreover, the frequency of osteopenia and osteoporosis in the women was 
increased. The reason was probably due to overtreatment with glucocorticoids, 
indicated by low androgens. 
Impaired fertility and fecundity were found in adult men with CAH. The most 
obvious cause is the presence of TARTs, but other causes probably contribute. In 
contrast to women with CAH, low fecundity does not seem to be mainly due to 
sexual orientation or psychosocial factors. Decreased semen quality was prevalent 
and patients with pathological semen also had more cardio-metabolic risk factors. The 
male with 3-beta-HSD deficiency was infertile. In spite of these findings, most males 
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with CAH due to 21-hydroxylase deficiency seemed to be able to father children 
eventually if they wished. 
Even though increased risks and worse outcomes were found in females and males with 
CAH the findings in this thesis were more positive than many of the previous reports 
on CAH. Many parameters studied in our CAH individuals < 30 years were in fact no 
different from age- and sex-matched controls. A larger study recently presented from 
United Kingdom indicated worse outcomes than our younger patients (Arlt et al 2010). 
One reason for a more favourable outcome for younger than older CAH patients in our 
cohort is most likely a better follow-up and management, especially during recent 
years. This emphasizes the importance of regular follow-ups of CAH women and men 
with lifestyle interventions and dose adjustments of corticoids, monitoring of 
anthropometric measurements, BMD, fractures, testicular ultrasound, and biochemical 
parameters together with a thorough clinical examination, as this seems to directely 
influence outcome. All patients in the present cohort were born before the introduction 
of neonatal screening. However, all CAH indivdiuals born in Sweden entering 
adulthood nowadays have been screened so outcomes will most likely improve futher. 
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